Sign in Subscribe
Class action lawsuits

Centene Corporation Sued for Securities Fraud

Strategic Insights

— 1 min read

Investors in Centene Corporation, a healthcare company that serves consumers in government-sponsored healthcare programs, may have legal options after the company was sued for potential securities law violations. A lawsuit was filed against Centene and its senior executives, alleging that they made false statements about the company's financial guidance and enrollment growth. The stock price of Centene declined significantly after the truth about the company's financial situation was revealed.

Key Takeaways:

  • A lawsuit was filed against Centene Corporation and its senior executives for potential securities law violations.
  • The complaint alleges that Centene made false statements about its financial guidance and enrollment growth.
  • Centene's stock price declined by over 40% after the truth about the company's financial situation was revealed.
  • Investors have until September 8, 2025, to ask the Court to be appointed to lead the case.
  • The case is pending in the U.S. District Court for the Southern District of New York and is captioned: Lunstrum v. Centene Corporation, et al., No. 25-cv-05659.
  • The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities.
  • Centene's financial guidance was repeatedly increased between December 2024 and April 2025, despite lower than expected enrollment growth and increased morbidity rates in the majority of the markets it serves.
  • The company's independent actuarial report from Wakely Consulting Group revealed lower than expected enrollment growth and higher morbidity rates in 22 of the 29 states Centene serves.
  • A leading international law firm, Bleichmar Fonti & Auld LLP, is representing the plaintiffs in the case and has a successful track record of recovering significant sums in securities class actions.

Statistics:

  • $22.87: Percentage decline in Centene stock price from $56.65 per share to $33.78 per share on July 2, 2025.
  • 40%: Decline in Centene stock price following the revelation of the company's true financial situation.
  • $900 million: Amount recovered by Bleichmar Fonti & Auld LLP from Tesla, Inc.'s Board of Directors.
  • $420 million: Amount recovered by Bleichmar Fonti & Auld LLP from Teva Pharmaceutical Ind. Ltd.

Sources:

  • Globe Newswire, "Leading Securities Law Firm Announces Class Action Lawsuit Against Centene Corporation (NYSE: CNC)"
  • SEC Class Action News, "Lunstrum v. Centene Corporation, et al. (25-cv-05659)"
  • Bleichmar Fonti & Auld LLP, "Recent Notable Successes"
  • Law360, "Titans of the Plaintiffs' Bar"

Read more